Citation: Annals of Cardiothoracic Surgery. 7(6):776-779, 2018 Nov..Journal: Annals of cardiothoracic surgery.Published: ; 2018ISSN: 2225-319X.Full author list: Beller JP; Rogers JH; Thourani VH; Ailawadi G.UI/PMID: 30598892.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): EditorialOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.21037/acs.2018.10.01 (Click here)Abbreviated citation: Ann. cardiothorac. surg.. 7(6):776-779, 2018 Nov.Abstract: Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.